Proposed Collection; Comment Request for Regulation Project, 15043-15044 [2019-07230]

Download as PDF 15043 Federal Register / Vol. 84, No. 71 / Friday, April 12, 2019 / Notices NON-PROBABILITY SAMPLE Number of respondents Category of respondent/activity Participation time (minutes) Burden hours Read Invitation Email ................................................................................................................... Read Reminder Email * ............................................................................................................... Complete Survey ......................................................................................................................... 461,540 431,540 60,000 0.5 0.25 ** 5.5 3,846 1,798 5,500 Total Burden Hours .............................................................................................................. ........................ ........................ 11,144 * The estimate for the Reminder emails is based on the assumption that 50% of the needed respondents will complete the survey online in time to not receive the Reminder email. ** Participant time is based on mean completion time for non-probability panel members during pilot survey fielding. The following paragraph applies to all of the collections of information covered by this notice: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103. Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. Comments will be of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information has practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information. Approved: April 8, 2019. Laurie Brimmer, Senior Tax Analyst. [FR Doc. 2019–07228 Filed 4–11–19; 8:45 am] BILLING CODE 4830–01–P jbell on DSK30RV082PROD with NOTICES DEPARTMENT OF THE TREASURY Internal Revenue Service Proposed Collection; Comment Request for Regulation Project Internal Revenue Service (IRS), Treasury. AGENCY: VerDate Sep<11>2014 18:18 Apr 11, 2019 Jkt 247001 Notice and request for comments. ACTION: The Internal Revenue Service, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on continuing information collections, as required by the Paperwork Reduction Act of 1995. The IRS is soliciting comments concerning annual registration statement identifying separated participants with deferred vested benefits. SUMMARY: Written comments should be received on or before June 11, 2019 to be assured of consideration. ADDRESSES: Direct all written comments to Laurie Brimmer, Internal Revenue Service, Room 6529, 1111 Constitution Avenue NW, Washington, DC 20224. FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the form should be directed to Kerry Dennis, at (202) 317–5751 or Internal Revenue Service, Room 6529, 1111 Constitution Avenue NW, Washington DC 20224, or through the internet, at Kerry.Dennis@irs.gov. SUPPLEMENTARY INFORMATION: Title: Annual Registration Statement Identifying Separated Participants with Deferred Vested Benefits. OMB Number: 1545–2187. Form Number: Form 8955–SSA. Abstract: Form 8955–SSA, the designated successor to Schedule SSA (Form 5500), is used to satisfy the reporting requirements of Internal Revenue Code section 6057(a). Plan administrators of employee benefit plans subject to the vesting standards of ERISA section 203 use the form to report information about separated participants with deferred vested benefits under the plan. The information is generally given to the Social Security Administration (SSA), which provides the reported information to separated participants DATES: PO 00000 Frm 00133 Fmt 4703 Sfmt 4703 when they file for social security benefits. Current Actions: There is no change to this form. Type of Review: Extension of a currently approved collection. Affected Public: Businesses and other for-profit organizations. Estimated Number of Respondents: 200,000. Estimated Time per Respondent: 50 minutes. Estimated Total Annual Burden Hours: 166,000. The following paragraph applies to all of the collections of information covered by this notice. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103. Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information. E:\FR\FM\12APN1.SGM 12APN1 15044 Federal Register / Vol. 84, No. 71 / Friday, April 12, 2019 / Notices Approved: April 8, 2019. Laurie Brimmer, Senior Tax Analyst. [FR Doc. 2019–07230 Filed 4–11–19; 8:45 am] BILLING CODE 4830–01–P DEPARTMENT OF VETERANS AFFAIRS Tiered Pharmacy Copayments for Medications Update Department of Veterans Affairs. Notice. AGENCY: ACTION: This Department of Veterans Affairs (VA) Notice updates the information on Tier 1 medications. FOR FURTHER INFORMATION CONTACT: Joseph Duran, Director of Policy and Planning, Office of Community Care, Veterans Health Administration, Department of Veterans Affairs, 810 SUMMARY: methodologies set forth in Section 17.110, this Notice updates the list of Tier 1 medications. Not less than once per year, VA will identify a subset of multi-source medications as Tier 1 medications. Only medications that meet all of the criteria in paragraphs (b)(2)(i), (ii), and (iii) of Section 17.110 will be eligible to be considered Tier 1 medications, and only those medications that meet all of the criteria in paragraph (b)(2)(i) of this section will be assessed using the criteria in paragraphs (b)(2)(ii) and (iii). As of the date of this Notice, the Tier 1 medication list based on the methodologies in Section 17.110 will be posted on VA’s website (www.va.gov/ health) under the heading ‘‘Tier 1 Copay Medication List.’’ The following table is the Tier 1 Copay Medication List that is effective January 1, 2019, and will remain in effect until December 31, 2019. Condition VA product name Arthritis and Pain ................................................ Aspirin Buffered Tablet, Aspirin Chewable Tablet, Aspirin Enteric Coated Tablet, Allopurinol Tablet, Ibuprofen Tablet, Meloxicam Tablet, Naproxen Tablet. Clopidogrel Bisulfate Tablet, Warfarin Sodium Tablet. Alendronate Tablet. Atorvastatin Tablet, Gemfibrozil Tablet, Lovastatin Tablet, Niacin (Slo-Niacin) Tablet, Pravastatin Tablet, Rosuvastatin Calcium Tablet, Simvastatin Tablet. Donepezil Tablet, Memantine Hydrochloride (HCL) Tablet. Glipizide Tablet, Metformin HCL Tablet, Metformin HCL 24-hour (HR) Sustained Action (SA) Tablet, Pioglitazone HCL Tablet. Potassium SA Tablet, Potassium SA Dispersible Tablet. Omeprazole Enteric Coated (EC) Capsule, Pantoprazole Sodium EC Capsule, Ranitidine Tablet. Brimonidine 0.2% Solution, Dorzolamide 2%/Timolol 0.5% Solution, Latanoprost 0.005% Solution, Timolol Maleate 0.25% Solution, Timolol Maleate 0.5% Solution. Amlodipine Tablet, Amiodarone HCL Tablet, Aspirin (see Arthritis and Pain), Atenolol Tablet, Carvedilol Tablet, Chlorthalidone Tablet, Clonidine Tablet, Diltiazem 24-Hour Capsule, Diltiazem HCL Tablet, Enalapril Maleate Tablet, Furosemide Tablet, Hydrochlorothiazide Capsule/Tablet, Hydrochlorothiazide/Lisinopril Tablet, Hydrochlorothiazide/Triamteren Capsule/Tablet, Isosorbide Mononitrate SA Tablet, Lisinopril Tablet, Losartan Tablet, Metoprolol Succinate SA Tablet, Metoprolol Tartrate Tablet, Nifedipine SA Capsule, Nitroglycerin Sublingual Tablet, Prazosin HCL Capsule, Propranolol HCL Tablet, Spironolactone Tablet, Valsartan Tablet, Verapamil HCL Tablet, Verapamil HCL SA Tablet. Amitriptyline HCL Tablet, Bupropion HCL Tablet, Bupropion HCL SA (12–HR Sustained Release) Tablet, Bupropion HCL SA (24–HR Extended Release XL) Tablet, Buspirone HCL Tablet, Citalopram Hydrobromide Tablet, Duloxetine HCL EC Capsule, Escitalopram Oxalate Tablet, Fluoxetine Capsule/Tablet, Lithium Carbonate Capsule/Tablet, Mirtazapine Tablet, Paroxetine HCL Tablet, Sertraline HCL Tablet, Trazodone Tablet, Venlafaxine HCL Tablet, Venlafaxine HCL SA Tablet/Capsule. Montelukast NA Tablet. Gabapentin Capsule, Lamotrigine Tablet, Topiramate Tablet. Levothyroxine Sodium Tablet. Alfuzosin HCL SA Tablet, Doxazosin Mesylate Tablet, Finasteride Tablet, Oxybutynin Chloride Tablet, Oxybutynin Chloride SA Tablet, Tamsulosin HCL Capsule, Terazosin HCL Capsule. Blood Thinners and Platelet Inhibitors ............... Bone Health ........................................................ Cholesterol .......................................................... Dementia ............................................................. Diabetes .............................................................. Electrolyte Supplement ....................................... Gastrointestinal Health ....................................... Glaucoma and Eye Care .................................... Heart Health and Blood Pressure ...................... Mental Health ...................................................... Respiratory Condition ......................................... Seizures .............................................................. Thyroid Conditions .............................................. Urologic (Bladder and Prostate) Health ............. Signing Authority jbell on DSK30RV082PROD with NOTICES Vermont Avenue NW, Washington, DC 20420; email: Joseph.Duran2@va.gov; telephone: (303) 372–4629 (this is not a toll-free number). SUPPLEMENTARY INFORMATION: Section 17.110 of Title 38 CFR governs copayments for medications that VA provides to Veterans. Section 17.110 provides the methodologies for establishing the copayment amount for each 30-day or less supply of medication provided by VA on an outpatient basis (other than medication administered during treatment). Section 17.110 provides a list of Tier 1 medications that will be published as a Notice in the Federal Register and will be posted on VA’s website (www.va.gov/health) at least once per year. Tier 1 medication means a multisource medication that has been identified using the process described in Section 17.110(b)(2). 38 CFR Section 17.110(b)(1)(iv)(B). Based on the The Secretary of Veterans Affairs, or designee, approved this document and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs. Robert L. Wilkie, Secretary, Department VerDate Sep<11>2014 18:18 Apr 11, 2019 Jkt 247001 of Veterans Affairs, approved this document on March 14, 2019, for publication. PO 00000 Dated: April 9, 2019. Luvenia Potts, Program Specialist, Office of Regulation Policy & Management, Office of the Secretary, Department of Veterans Affairs. [FR Doc. 2019–07336 Filed 4–11–19; 8:45 am] BILLING CODE 8320–01–P Frm 00134 Fmt 4703 Sfmt 9990 E:\FR\FM\12APN1.SGM 12APN1

Agencies

[Federal Register Volume 84, Number 71 (Friday, April 12, 2019)]
[Notices]
[Pages 15043-15044]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07230]


-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

Internal Revenue Service


Proposed Collection; Comment Request for Regulation Project

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: The Internal Revenue Service, as part of its continuing effort 
to reduce paperwork and respondent burden, invites the general public 
and other Federal agencies to take this opportunity to comment on 
continuing information collections, as required by the Paperwork 
Reduction Act of 1995. The IRS is soliciting comments concerning annual 
registration statement identifying separated participants with deferred 
vested benefits.

DATES: Written comments should be received on or before June 11, 2019 
to be assured of consideration.

ADDRESSES: Direct all written comments to Laurie Brimmer, Internal 
Revenue Service, Room 6529, 1111 Constitution Avenue NW, Washington, DC 
20224.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or 
copies of the form should be directed to Kerry Dennis, at (202) 317-
5751 or Internal Revenue Service, Room 6529, 1111 Constitution Avenue 
NW, Washington DC 20224, or through the internet, at 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Title: Annual Registration Statement Identifying Separated 
Participants with Deferred Vested Benefits.
    OMB Number: 1545-2187.
    Form Number: Form 8955-SSA.
    Abstract: Form 8955-SSA, the designated successor to Schedule SSA 
(Form 5500), is used to satisfy the reporting requirements of Internal 
Revenue Code section 6057(a). Plan administrators of employee benefit 
plans subject to the vesting standards of ERISA section 203 use the 
form to report information about separated participants with deferred 
vested benefits under the plan. The information is generally given to 
the Social Security Administration (SSA), which provides the reported 
information to separated participants when they file for social 
security benefits.
    Current Actions: There is no change to this form.
    Type of Review: Extension of a currently approved collection.
    Affected Public: Businesses and other for-profit organizations.
    Estimated Number of Respondents: 200,000.
    Estimated Time per Respondent: 50 minutes.
    Estimated Total Annual Burden Hours: 166,000.
    The following paragraph applies to all of the collections of 
information covered by this notice.
    An agency may not conduct or sponsor, and a person is not required 
to respond to, a collection of information unless the collection of 
information displays a valid OMB control number. Books or records 
relating to a collection of information must be retained as long as 
their contents may become material in the administration of any 
internal revenue law. Generally, tax returns and tax return information 
are confidential, as required by 26 U.S.C. 6103.
    Request for Comments: Comments submitted in response to this notice 
will be summarized and/or included in the request for OMB approval. All 
comments will become a matter of public record. Comments are invited 
on: (a) Whether the collection of information is necessary for the 
proper performance of the functions of the agency, including whether 
the information shall have practical utility; (b) the accuracy of the 
agency's estimate of the burden of the collection of information; (c) 
ways to enhance the quality, utility, and clarity of the information to 
be collected; (d) ways to minimize the burden of the collection of 
information on respondents, including through the use of automated 
collection techniques or other forms of information technology; and (e) 
estimates of capital or start-up costs and costs of operation, 
maintenance, and purchase of services to provide information.


[[Page 15044]]


    Approved: April 8, 2019.
Laurie Brimmer,
Senior Tax Analyst.
[FR Doc. 2019-07230 Filed 4-11-19; 8:45 am]
 BILLING CODE 4830-01-P